Indivi operates at the intersection of mobile computing and clinical neuroscience, building smartphone-based digital endpoints for precision medicine. The core platform functions as a "digital measurement laboratory" - capturing behavioral and physiological signals from consumer devices to quantify outcomes in neurology and neurodegenerative disorders. This is sensor data at population scale feeding into drug development pipelines, which means the attack surface spans personal health information, device telemetry, and clinical trial datasets.
The technical stack draws on software development, data science, machine learning, and artificial intelligence, with clinical science baked into the product design. That blend matters: the analytics layer processes sensitive patient-generated data in contexts where regulatory compliance - HIPAA, GDPR, and clinical trial data integrity requirements - is non-negotiable. Protecting the integrity and confidentiality of that data isn't a side function; it's foundational to whether pharma partners trust the platform.
Based in Basel, Switzerland, Indivi focuses on neuroscience research, drug development, and treatment of neurodegenerative disorders. The security challenge here is specific: a compromised measurement pipeline doesn't just risk a data breach - it could undermine the evidentiary basis of a clinical endpoint, with downstream consequences for drug approval. Teams working here would be securing systems where data provenance, device integrity, and cryptographic assurance have direct clinical stakes.
